Serono and Syntonix Pharmaceuticals entered into an agreement under which the companies will evaluate Syntonix’ FSH:Fc SynFusion™ products for further development. Syntonix’ SynFusion and Transceptor™ technologies may enable the development of a long-acting FSH therapy for the treatment of infertility that can be inhaled and dosed less frequently, instead of injected daily, explains officials at both firms.
Syntonix has provided Serono with an exclusive option to license exclusive, worldwide rights for the development and commercialization of Syntonix’ FSH:Fc SynFusion drugs. Serono will decide whether to exercise the option after further evaluation of the FSH:Fc candidates.
Serono will pay Syntonix a collaboration and option fee. If Serono exercises the option, Syntonix will receive an additional upfront license fee and will be eligible for milestone fees (total worth up to $54 million), as well as royalties upon commercialization.
